Barbara E Bierer

Barbara Emily Bierer, MD

Professor of Medicine (Pediatrics), HMS
Member, HMS Center for Bioethics

Barbara Bierer, MD is a Professor of Medicine (Pediatrics) at Harvard Medical School (HMS), and a hematologist/oncologist at the Brigham and Women's Hospital (BWH). She received her MD from HMS. She is the director of the Regulatory Foundations, Law and Ethics Program of the Harvard Catalyst, the Harvard Clinical and Translational Science Award, and the director of regulatory policy, SMART IRB. Dr. Bierer co-founded and now leads the Multi-Regional Clinical Trials Center of BWH and Harvard (MRCT Center), a University-wide and collaborative effort to improve the ethics, conduct, and regulatory environment for multi-site, multi-national clinical trials. She is a co-founder of COVID-19 Collaboration Platform, a platform for cooperation in research. In 2017, the MRCT Center launched the non-profit Vivli, a global clinical research data sharing platform. From 2003-2014, she served as Senior Vice President, Research, at BWH and was the institutional official for human subjects and animal research, for biosafety and for research integrity at the BWH. She initiated the Brigham Research Institute and the Innovation Hub (iHub), a focus for entrepreneurship and innovation. Dr. Bierer established and directed the Center for Faculty Development and Diversity at the BWH; for these efforts, she was the first recipient of the HMS Harold Amos Faculty Diversity Award.

Publications View
Calcineurin phosphatase activity in T lymphocytes is inhibited by FK 506 and cyclosporin A.
Authors: Authors: Fruman DA, Klee CB, Bierer BE, Burakoff SJ.
Proc Natl Acad Sci U S A
View full abstract on Pubmed
T cell receptor activation of a ribosomal S6 kinase activity.
Authors: Authors: Calvo V, Bierer BE, Vik TA.
Eur J Immunol
View full abstract on Pubmed
FK 506 and rapamycin: molecular probes of T-lymphocyte activation.
Authors: Authors: Bierer BE, Jin YJ, Fruman DA, Calvo V, Burakoff SJ.
Transplant Proc
View full abstract on Pubmed
CD43, a molecule defective in Wiskott-Aldrich syndrome, binds ICAM-1.
Authors: Authors: Rosenstein Y, Park JK, Hahn WC, Rosen FS, Bierer BE, Burakoff SJ.
Nature
View full abstract on Pubmed
Selective depletion of bone marrow T lymphocytes with anti-CD5 monoclonal antibodies: effective prophylaxis for graft-versus-host disease in patients with hematologic malignancies.
Authors: Authors: Antin JH, Bierer BE, Smith BR, Ferrara J, Guinan EC, Sieff C, Golan DE, Macklis RM, Tarbell NJ, Lynch E, et al.
Blood
View full abstract on Pubmed
Molecular cloning of a membrane-associated human FK506- and rapamycin-binding protein, FKBP-13.
Authors: Authors: Jin YJ, Albers MW, Lane WS, Bierer BE, Schreiber SL, Burakoff SJ.
Proc Natl Acad Sci U S A
View full abstract on Pubmed
Interaction of CD2 with its ligand lymphocyte function-associated antigen-3 induces adenosine 3',5'-cyclic monophosphate production in T lymphocytes.
Authors: Authors: Hahn WC, Rosenstein Y, Burakoff SJ, Bierer BE.
J Immunol
View full abstract on Pubmed
Enhancement of T-cell activation by the CD43 molecule whose expression is defective in Wiskott-Aldrich syndrome.
Authors: Authors: Park JK, Rosenstein YJ, Remold-O'Donnell E, Bierer BE, Rosen FS, Burakoff SJ.
Nature
View full abstract on Pubmed
The effect of the immunosuppressant FK-506 on alternate pathways of T cell activation.
Authors: Authors: Bierer BE, Schreiber SL, Burakoff SJ.
Eur J Immunol
View full abstract on Pubmed
T cell receptors: adhesion and signaling.
Authors: Authors: Bierer BE, Burakoff SJ.
Adv Cancer Res
View full abstract on Pubmed